Skip to main content
TipRanks
Go Ultimate75% OFF

Windlas Biotech Ltd. (WINDLAS) AI Stock Analysis

2 Followers
IN:WINDLAS

Windlas Biotech Ltd.

(NSE:WINDLAS)

Select Model
Rating:63Neutral
Price Target:INR 1,060.00â–²(7.22% Upside)
Action:reiterated
Date:11/07/26

Windlas Biotech scores moderately above average, driven primarily by a strong growth record and an exceptionally clean, low-debt balance sheet that gives it flexibility to fund expansion. The main drags are a sharply projected gross margin decline in FY2026 estimates and highly volatile free cash flow generation, which together raise questions about earnings quality and margin sustainability. Technically, the stock remains in a longer-term uptrend above its 100- and 200-day averages, though a negative MACD and a slip below the 50-day average signal a short-term consolidation. Valuation at ~31x earnings with a modest 0.63% yield prices in continued growth, leaving limited room for execution missteps. Earnings call and corporate event data were unavailable and excluded, with their weight redistributed across the remaining components.

Positive Factors
Sustained Revenue GrowthStrong multi-year revenue growth indicates expanding demand for Windlas Biotech’s offerings and a proven ability to scale over time. Continued top-line momentum can support operating investment, broaden customer relationships, and strengthen the company’s position in pharmaceutical manufacturing.
Negative Factors
Gross Margin CompressionThe sharp FY2026 gross-margin decline raises questions about the durability of the company’s profitability and the economics of recent growth. If margins remain below historical levels, operating leverage may weaken and future revenue gains could translate less effectively into earnings.

Windlas Biotech Ltd. (WINDLAS) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%50%IN:WINDLAS+25.52%INDA-5.96%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 20.61B
Dividend Yield
0.64%
Average Volume (3M)
6,337
Price to Earnings (P/E)
30.9
Beta (1Y)
0.96
Revenue Growth
18.48%
EPS Growth
-0.41%
Country
India
Employees
1,385
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Windlas Biotech Ltd. Business Overview & Revenue Model

Company Description

Windlas Biotech Limited functions as a comprehensive contract development and manufacturing organization (CDMO). Its CDMO offerings span the full product lifecycle, encompassing initial discovery, subsequent development, licensing, and large-scale co...

Windlas Biotech Ltd. Financial Statement Overview

Summary

Revenue has nearly doubled over five years (₹4.27B in FY2021 to ₹7.60B in FY2025, with ₹9.04B projected for FY2026) and net income has grown from ₹158M to ₹610M, earning a solid Income Statement score of 68. The balance sheet is the standout strength (score 78), with near-zero leverage (D/E of 0.008–0.064), steadily compounding equity to ₹5.06B, and total assets expanding to ₹7.60B — rare financial discipline in capital-intensive pharma manufacturing. Offsetting this, cash flow is the weak link (score 55): free cash flow has swung from negative in FY2022–FY2023 to ₹713M in FY2024 before collapsing to ₹160M in FY2025, pointing to lumpy capex and heavy working capital swings and unreliable cash conversion. The projected gross margin compression from ~38% to ~18% and EBITDA margin slide to ~11.6% in FY2026 estimates is a material concern that caps the score.

Income Statement

68Positive

Balance Sheet

78Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue9.84B9.04B7.60B6.29B5.11B4.63B
Gross Profit1.72B1.64B2.88B2.28B1.81B1.61B
EBITDA1.15B1.05B1.12B916.40M701.91M591.29M
Net Income666.97M664.56M609.94M581.87M426.26M380.89M
Balance Sheet
Total Assets10.15B9.07B7.60B6.26B5.29B4.91B
Cash, Cash Equivalents and Short-Term Investments2.62B2.70B2.40B2.04B1.32B1.76B
Total Debt534.29M352.42M325.97M36.41M49.93M66.37M
Total Liabilities4.46B3.27B2.55B1.76B1.27B962.33M
Stockholders Equity5.69B5.81B5.06B4.50B4.02B3.95B
Cash Flow
Free Cash Flow0337.68M159.93M712.76M-99.25M-56.74M
Operating Cash Flow01.01B681.87M1.09B609.65M91.30M
Investing Cash Flow0-931.15M-740.64M-920.68M-141.10M-1.55B
Financing Cash Flow0-82.06M10.13M-152.90M-437.39M1.30B

Windlas Biotech Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price988.60

Price Trends

50DMA1009.11Negative
100DMA951.91Positive
200DMA873.90Positive

Market Momentum

MACD6.06Negative
RSI56.22Neutral
STOCH66.03Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WINDLAS, the sentiment is Positive. The current price of 988.60 is above the 20-day moving average (MA) of 927.69, below the 50-day MA of 1009.11, and above the 200-day MA of 873.90, indicating a neutral trend. The MACD of 6.06 indicates Negative momentum. The RSI at 56.22 is Neutral, neither overbought nor oversold. The STOCH value of 66.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:WINDLAS.

Windlas Biotech Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:WINDLAS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SYNCOMFIN:SYNCOMF79OutperformINR 20.74B24.26―0.45%0.44%48.60%
IN:VENUSREMIN:VENUSREM72OutperformINR 19.37B15.98―0.69%20.22%73.03%
IN:WINDLASIN:WINDLAS63NeutralINR 20.40B30.89―0.64%18.48%-0.41%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:MOREPENLABIN:MOREPENLAB55NeutralINR 50.55B26.93―0.22%30.20%91.17%
IN:INDSWFTLABIN:INDSWFTLAB51NeutralINR 29.21B34.50――66.39%-72.31%
IN:INDOCOIN:INDOCO48NeutralINR 22.26B71.18―0.08%10.75%―

* General Sector Average

Performance Comparison

0%100%200%300%IN:WINDLASIN:INDOCOIN:INDSWFTLABIN:MOREPENLABIN:SYNCOMFIN:VENUSREMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:WINDLAS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:WINDLASWindlas Biotech Ltd.988.60188.9423.63%
IN:INDOCOIndoco Remedies Limited241.15-10.18-4.05%
IN:INDSWFTLABInd-Swift Laboratories Ltd.335.90240.50252.10%
IN:MOREPENLABMorepen Laboratories Limited92.2547.33105.34%
IN:SYNCOMFSyncom Formulation (India) Ltd.22.066.1538.65%
IN:VENUSREMVenus Remedies Limited1449.30762.87111.14%

Windlas Biotech Ltd. Corporate Events

Windlas Biotech Schedules Earnings Call for Q2 and H1 FY27 Results

Oct 30, 2026

Windlas Biotech Limited operates in the pharmaceutical and biotechnology sector, producing healthcare and biopharmaceutical products for the Indian market and beyond. The company is publicly listed on BSE and NSE, signaling its integration into India...

Windlas Biotech Files Q1 FY27 Earnings Call Transcript With Indian Exchanges

Aug 14, 2026

Windlas Biotech Limited has released the transcript of its Q1 FY27 earnings conference call, formally submitting the document to the listing and compliance departments of BSE and the National Stock Exchange of India in line with SEBI disclosure regul...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026